Comparison of simple tests for the non-invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 5, 2006, Pages 797-804

  Borroni, G ^a,e   Ceriani, R ^b   Cazzaniga, M ^c   Tommasini, M ^b   Roncalli, M ^b   Maltempo, C ^a   Felline, C ^a   Salerno, F ^d  

^a Dipartimento Dipendenze   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e ASL Provincia di Milano 1   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADOLESCENT; ADULT; AGE PLATELET INDEX; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE TRANSAMINASE ALANINE TRANSAMINASE RATIO; ASPARTATE TRANSMINASE TO PLATELET RATIO INDEX; CIRRHOSIS DISCRIMINANT SCORE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INVASIVE MEASUREMENT; POHL INDEX; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; THROMBOCYTE;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; DIAGNOSTIC TESTS, ROUTINE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROTHROMBIN TIME; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33747374031     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03034.x     Document Type: Review

References (27)

1. Gretch DR, dela Rosa C, Carithers RL, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlation and clinical implications. Ann Intern Med 1995; 123: 321-9.
2. Gross JB, Persing DH. Hepatitis C: advances in diagnosis. Mayo Clin Proc 1995; 70: 296-7.
3. Davis JB, Lau JYN, Lim HL. Therapy for chronic hepatitis C. Gastroenterol Clin North Am 1994; 23: 603-13.
4. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68276 biopsies. J 'Hepatol 1986; 2: 165-73.
5. Poniachik J, Bernstein DE, Reddy KR, et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996; 43: 568-71.
6. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
7. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26: 57S-61S.
8. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alfa in cirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Francais pour l'Etude du Traitement des Hepatites Chroniques NANB/C. Gastroenterology 1994; 106: 686-90.
9. Van Leeuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid-1990s: questions and answers. Semin Liver Dis 1995; 15: 340-59.
10. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
11. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis. Gastroenterology 1988; 95: 734-9.
12. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92: 1302-4.
13. Wai CT, Greenson JK, Fontana RJ, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
14. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-6.
15. Poynard T, Bedossa P, METAVIR and CLINIVIR cooperative study groups. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepat 1997; 4: 199-208.
16. Hanley HA, McNeil BJ. The meaning and the use of the area under the receiver operating characteristic (ROC) curve. Radiology 1982; 142: 29-36.
17. McGee S. Evidence-Based Physical Diagnosis. Philadelphia: , 2001: 594-614.
18. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-83.
19. Fontana RJ, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36: S57-64.
20. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-48.
21. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-24.
22. Reedy DW, Loo AT, Levine RA. AST/ALT ratio ≥1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998; 43: 2156-9.
23. Imperiale FI, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000; 95: 2328-32.
24. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b for initial treatment of chronic hepatitis C : a randomised trial. Lancet 2001; 358: 958-65.
25. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
26. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-82.
27. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.